Results 111 to 120 of about 39,993 (263)

Report of the second dementia with Lewy body international workshop - Diagnosis and treatment

, 1996
Background/Objective: The second International Workshop of the Consortium on Dementia with Lewy Bodies (DLB) met to review developments since publication of consensus guidelines for the clinical and pathologic diagnosis of DLB in 1996. The specificity of
and for the Consortium on Dementia with Lewy Bodies, McKeith IG, Perry EK, Perry RH   +3 more
core  

Tracking Genetic Parkinson's Disease with Molecular Imaging: A Systematic Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) is a worldwide, complex neurodegenerative disorder influenced by both genetic and environmental factors. Around 15–20% of PD cases are linked to genetic mutations, providing insights into the disease's pathogenesis.
Chiara Meneghini, Luca Gallo, Arianna Sala, Enza Maria Valente, Micol Avenali, Silvia Paola Caminiti   +5 more
wiley   +1 more source

LEWY BODY VARIANT OF ALZHEIMER DISEASE

Zdravniški Vestnik, 2003
Background. Clinicopathological studies indicate that Alzheimer’s disease (AD) is the most common neurodegenerative cause of dementia, the other frequent causes are AD combined with diffuse Lewy bodies and dementia with Lewy bodies (DLB) by itself.
Jera Jeruc, Aleš Kogoj, Marko Pišljar, Mara Popović   +3 more
doaj  

Apathy in Parkinson's Disease: Distinguishing Overlapping Symptoms Via Network Analysis

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Anxiety, fatigue, and excessive daytime sleepiness (EDS) frequently co‐occur in Parkinson's disease (PD) and can influence the clinical determination of apathy. Objective To distinguish patient‐reported apathy from other non‐motor symptoms.
Joseph Seemiller, Abhimanyu Mahajan, Christopher B. Morrow, Joseph F. McGuire, Dawn Bowers, Kelly A. Mills, Gregory M. Pontone   +6 more
wiley   +1 more source

Delphi consensus guidelines for the use of striatal dopaminergic imaging and cardiac metaiodobenzylguanidine (MIBG) scintigraphy for the diagnosis of dementia and mild cognitive impairment with Lewy bodies

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION The aim of this Delphi process was to develop consensus guidelines to support the effective use of striatal dopaminergic imaging and cardiac metaiodobenzylguanidine (MIBG) scintigraphy in the diagnosis of dementia with Lewy bodies and mild ...
Paul C. Donaghy, Gemma Greenfinch, George Petrides, Joseph Kane, Hein J. Verberne, John‐Paul Taylor, John T. O'Brien, Alan J. Thomas, DLB Indicative Imaging Biomarker Study Group   +8 more
doaj   +1 more source

DEMENTIA WITH LEWY BODIES: A CASE REPORT

Psychiatry and Clinical Psychopharmacology, 2021
Following the description of Lewy body spectrum disorders by Kosaka in 1980, dementia with Lewy bodies (DLB) which was considered as a rare cause of dementia before, is much more frequently recognized. DLB can be considered as being a member of spectrum
Sermin Kesebir, Demet Gülpek, Nuri Doğan Atalay, Erhan Bayraktar   +3 more
doaj  

Differential Progression of Neuroinflammation in Patients with Isolated Rapid‐Eye‐Movement Sleep Behavior Disorder

Movement Disorders, EarlyView.
Abstract Background Neuroinflammation, measured using [11C](R)‐PK11195 positron emission tomography (PET), has been reported in isolated rapid‐eye‐movement sleep behavior disorder (iRBD), but its temporal progression is unknown. Objective The aim was to assess longitudinal progression of neuroinflammation in iRBD patients and its relationship with ...
Andreas Myhre Baun, Alex Iranzo, Miriam Højholt Terkelsen, Rainer Hinz, Morten Gersel Stokholm, Kristian Stær, Mónica Serradel, Marit Otto, Kristina Bacher Svendsen, Alicia Garrido, Dolores Vilas, Arne Møller, Carles Gaig, Eduardo Tolosa, David J. Brooks, Per Borghammer, Simon Fristed Eskildsen, Nicola Pavese   +17 more
wiley   +1 more source

Safety and efficacy of pimavanserin in patients with Lewy body dementia experiencing dementia-related psychosis in the HARMONY study

BMC Neurology
Background Pimavanserin is approved by the US Food and Drug Administration for the treatment of hallucinations and delusions associated with Parkinson’s disease.
Yasar Torres-Yaghi, Lambros Chrones, Victor Abler, Greg Brunson   +3 more
doaj   +1 more source

From Molecular Pathology to Cognitive Phenotypes: The Emerging Role of Artificial Intelligence in Neuroimaging

iRADIOLOGY, EarlyView.
Xiaohui Zhang, Yan Zhong, Rui Zhou, Chentao Jin, Jing Wang, Mei Tian, Hong Zhang   +6 more
wiley   +1 more source

[18F]Fluorodeoxyglucose positron emission tomography ([18F]FDG PET) Characterizes Neurodegeneration Levels Across the α‐Synucleinopathy Continuum

Movement Disorders, EarlyView.
Abstract Background [18F]Fluorodeoxyglucose positron emission tomography ([18F]FDG PET) represents an endorsed neurodegeneration biomarker in neuronal α‐synucleinopathies. Idiopathic/isolated rapid eye movement (REM) sleep behavior disorder (iRBD) represents a prodromal stage of such disorders.
Beatrice Orso, Ignacio Roura, Pietro Mattioli, Francesco Famà, Federico Massa, Luigi Lorenzini, Andrea Brugnolo, Nicola Girtler, Mattia Losa, Stefano Raffa, Luca Sofia, Monica Roascio, Gabriele Arnulfo, Silvia Morbelli, Matteo Pardini, Dario Arnaldi   +15 more
wiley   +1 more source